...
首页> 外文期刊>Clinical epigenetics. >MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma
【24h】

MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma

机译:MicroRNA-101被EZH2抑制,其恢复抑制胚胎横纹肌肉瘤的致瘤特征

获取原文
           

摘要

BackgroundRhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that have lost their capability to differentiate into skeletal muscle. The polycomb-group protein EZH2 is a Lys27 histone H3 methyltransferase that regulates the balance between cell proliferation and differentiation by epigenetically silencing muscle-specific genes. EZH2 is often over-expressed in several human cancers acting as an oncogene. We previously reported that EZH2 inhibition induces cell cycle arrest followed by myogenic differentiation of RMS cells of the embryonal subtype (eRMS). MiR-101 is a microRNA involved in a negative feedback circuit with EZH2 in different normal and tumor tissues. To that, miR-101 can behave as a tumor suppressor in several cancers by repressing EZH2 expression. We, therefore, evaluated whether miR-101 is de-regulated in eRMS and investigated its interplaying with EZH2 as well as its role in the in vitro tumorigenic potential of these tumor cells. ResultsHerein, we report that miR-101 is down-regulated in eRMS patients and in tumor cell lines compared to their controls showing an inverse pattern of expression with EZH2. We also show that miR-101 is up-regulated in eRMS cells following both genetic and pharmacological inhibition of EZH2. In turn, miR-101 forced expression reduces EZH2 levels as well as restrains the migratory potential of eRMS cells and impairs their clonogenic and anchorage-independent growth capabilities. Finally, EZH2 recruitment to regulatory region of miR-101-2 gene decreases in EZH2-silenced eRMS cells. This phenomenon is associated to reduced H3K27me3 levels at the same regulatory locus, indicating that EZH2 directly targets miR-101 for repression in eRMS cells. ConclusionsAltogether, our data show that, in human eRMS, miR-101 is involved in a negative feedback loop with EZH2, whose targeting has been previously shown to halt eRMS tumorigenicity. They also demonstrate that the re-induction of miR-101 hampers the tumor features of eRMS cells. In this scenario, epigenetic dysregulations confirm their crucial role in the pathogenesis of this soft tissue sarcoma.
机译:背景横纹肌肉瘤(RMS)是一种小儿软组织肉瘤,由成肌前体引起,它们已经失去了分化为骨骼肌的能力。聚梳组蛋白EZH2是Lys27组蛋白H3甲基转移酶,通过表观遗传沉默肌肉特异性基因来调节细胞增殖与分化之间的平衡。 EZH2通常在几种人类癌基因中过表达。我们先前曾报道,EZH2抑制诱导细胞周期停滞,继之以胚胎亚型(eRMS)的RMS细胞成肌分化。 MiR-101是一种微小RNA,与正常组织和肿瘤组织中的EZH2负反馈回路有关。为此,miR-101可通过抑制EZH2表达而在多种癌症中发挥抑癌作用。因此,我们评估了miR-101是否在eRMS中失控,并研究了其与EZH2的相互作用以及其在这些肿瘤细胞体外致瘤性中的作用。结果在这里,我们报道与他们的对照相比,eRMS患者和肿瘤细胞系中的miR-101被下调,显示与EZH2的表达相反。我们还显示,在ERMS2的遗传和药理学抑制作用下,eRMS细胞中的miR-101上调。反过来,miR-101的强制表达降低了EZH2的水平,并限制了eRMS细胞的迁移潜能,并削弱了它们的克隆形成和不依赖贴壁的生长能力。最后,EZH2沉默的eRMS细胞中EZH2募集到miR-101-2基因的调控区减少。此现象与在相同调节位点处的H3K27me3水平降低有关,表明EZH2直接靶向miR-101来抑制eRMS细胞。结论总而言之,我们的数据表明,在人类eRMS中,miR-101参与了EZH2的负反馈环,EZH2的靶向先前已显示出可以阻止eRMS致瘤性。他们还证明,miR-101的重新诱导会阻碍eRMS细胞的肿瘤特征。在这种情况下,表观遗传失调证实了它们在这种软组织肉瘤的发病机理中的关键作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号